Adjuvant therapy for breast cancer — results from the USA consensus conference
- 1 October 2001
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 8 (4), 298-304
- https://doi.org/10.1007/bf02967528
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI Journal of the National Cancer Institute, 2001
- Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized TrialJournal of Clinical Oncology, 2000
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancerBritish Journal of Cancer, 1996
- Treatment of Early-Stage Breast CancerJAMA, 1991
- Adjuvant Chemotherapy for Breast CancerPublished by American Medical Association (AMA) ,1985
- Treatment of Primary Breast CancerPublished by American Medical Association (AMA) ,1980